文献速递淋巴瘤

在初治非生发中心B细胞样弥漫大B细胞淋巴瘤患者中比较R-CHOP联合或不联合硼替佐米的随机II期研究

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2017-09-01

该随机II期研究纳入206例初治非生发中心B细胞样弥漫大B细胞淋巴瘤患者,按1:1随机接受6周期标准R-CHOP或R-CHOP联合硼替佐米(VR-CHOP)治疗。在中位随访34个月后,VR-CHOP组无进展生存的风险比为0.73(90%CI 0.43-1.24,P=.611),未显著改善结局;两组总缓解率分别为98%和96%。

要点

  • VR-CHOP组2年无进展生存率为82.0%,R-CHOP组为77.6%,差异未达统计学显著。
  • 在高-中/高危IPI患者中,2年无进展生存率R-CHOP组65.1% vs VR-CHOP组72.4%(HR 0.67)。
  • ≥3级不良事件中,VR-CHOP组血小板减少29% vs R-CHOP组13%,神经病变5% vs 1%。

核心结论

  • 初治非生发中心B细胞样弥漫大B细胞淋巴瘤患者接受R-CHOP的结局优于预期,加用硼替佐米未显著改善结局。

研究设计与样本

  • 随机II期研究,采用Hans免疫组化算法实时判定非生发中心B细胞样弥漫大B细胞淋巴瘤后,将206例患者按1:1随机分组(按国际预后指数评分分层),接受6个21天周期的标准R-CHOP或R-CHOP联合硼替佐米1.3 mg/m2静脉注射(第1天和第4天)(VR-CHOP)。
  • 主要终点无进展生存在意向治疗人群中评估,实际分析183例经中心确认的非生发中心B细胞样弥漫大B细胞淋巴瘤且至少接受一剂研究药物的患者(R-CHOP组91例,VR-CHOP组92例)。

主要发现

  • 中位随访34个月,R-CHOP组25%、VR-CHOP组18%的患者发生无进展生存事件,VR-CHOP组无进展生存的风险比为0.73(90%CI 0.43-1.24,P=.611)。
  • 2年无进展生存率R-CHOP组为77.6%,VR-CHOP组为82.0%;在高-中/高危IPI患者中分别为65.1%和72.4%(HR 0.67,90%CI 0.34-1.29),在低/低-中危IPI患者中分别为90.0%和88.9%(HR 0.85,90%CI 0.35-2.10)。
  • 总缓解率R-CHOP组为98%,VR-CHOP组为96%;总生存的风险比为0.75(90%CI 0.38-1.45),2年生存率分别为88.4%和93.0%。
  • 安全性人群(R-CHOP组100例,VR-CHOP组101例)中,≥3级不良事件包括中性粒细胞减少(53% vs 49%)、血小板减少(13% vs 29%)、贫血(7% vs 15%)、白细胞减少(26% vs 25%)和神经病变(1% vs 5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP ( P = .611). Two-year PFS rates were 77.6% with R-CHOP and 82.0% with VR-CHOP; they were 65.1% versus 72.4% in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade ≥ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017. PMID: 28862883. doi:10.1200/JCO.2017.73.2784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。